From Zacks Investment Research: 2025-05-23 09:24:00

Novo Nordisk CEO, Lars Fruergaard Jørgensen, resigns amid increased competitive pressure and market challenges. Sanofi to acquire Vigil Neuroscience for $470 million to strengthen neurology pipeline. Pfizer strikes exclusive deal with Chinese biotech 3SBio for $1.25 billion upfront payment. FDA approves Roche’s eye drug Susvimo for diabetic retinopathy. Merck and Daiichi Sankyo begin pivotal study on ifinatamab deruxtecan in esophageal cancer. In the last five trading sessions, Merck rose the most while Lilly declined the most. Novartis rose the most in the past six months, while Novo Nordisk declined the most. Watch for regular pipeline and regulatory updates in the Pharma world next week.



Read more at Zacks Investment Research: Pharma Stock Roundup: NVO CEO Resigns, SNY to Buy VIGL & More – May 23, 2025